ECONOMIC EVALUATION OF MESALAZINE 4G (SALOFALK®) IN THE TREATMENT OF PATIENTS WITH ULCERATIVE COLITIS LOCATED IN THE RECTUM AND SIGMOID
Author(s)
Soto Molina H1, Perez-Gomez M2, Ochoa-Tamayo L2, Díaz Martínez JP3
1HS Estudios Farmacoeconómicos S.A. de C.V., Mexico City, Mexico, 2Schwabe Pharma México, Mexico, Mexico, 3HS Estudios Farmacoeconómicos, Mexico City, Mexico
OBJECTIVES: To carry out a complete economic evaluation of the use of mesalazine 4g for the treatment of ulcerative colitis located in the rectum and sigmoids from the perspective of the Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (ISSSTE) in Mexico. METHODS: A cost-effectiveness analysis was carried out through a Markov model comparing the use of mesalazine 4g and budesonide 2.3 mg. The comparator was defined based on a panel of experts (Delphi method). The model was supported with a network meta-analysis (Zhao, 2017). The time horizon of the model was 5 years and the measure of effectiveness was time in remission. Only direct medical costs were considered. An incremental cost-effectiveness analysis and a sensitivity analysis (deterministic and probabilistic) were performed. RESULTS: Mesalazine 4g was shown to have a longer mean time in remission versus budesonide 2.3 mg (4.2 years versus 4.08 years). Likewise, a lower average cost per patient was demonstrated for mesalazine 4g vs budesonide 2.3 mg ($6819.72 vs $8024.74), respectively. With the above results, it can be observed that in efficacy mesalazine 4g is a more effective and less expensive option than budesonide 2.3 mg with which it is verified that mesalazine 4g is a dominant option for the ISSSTE. The sensitivity analysis showed that the results are robust. CONCLUSIONS: Mesalazine 4g is a new effective and efficient option (greater efficiency and lower cost) for the treatment of patients with ulcerative colitis located in the rectum and sigmoids.
Conference/Value in Health Info
2018-11, ISPOR Europe 2018, Barcelona, Spain
Value in Health, Vol. 21, S3 (October 2018)
Code
PMU62
Topic
Economic Evaluation
Topic Subcategory
Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Gastrointestinal Disorders